High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
10
2020
accepted:
14
03
2021
entrez:
30
3
2021
pubmed:
31
3
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Trans women have been understudied in the Hepatitis C virus (HCV) epidemic, yet data suggest they may be at elevated risk of the disease. Using data collected from the Centers for Disease Control and Prevention's (CDC) National HIV Behavioral Surveillance (NHBS) survey, we measured HCV seropositivity, viremia, and associated risk factors for HCV infection among trans women in San Francisco from June 2019 to February 2020. Respondent-driven sampling (RDS) was used to obtain a diverse, community-based sample of 201 trans women, of whom 48 (23.9%, 95% CI 17.9% - 30.0%) were HCV seropositive. HCV seropositivity significantly increased with increasing age (adjusted prevalence ratio [APR] 1.04 per year, 95% CI 1.01-1.07) and history of injection drug use (APR 4.44, 95% CI 2.15-9.18). We also found that many had HCV viremia as twelve (6.0% of the total sample, 95% CI 2.7% - 9.3%) were RNA-positive for HCV. Trans women are highly impacted by HCV and could benefit from access to regular and frequent HCV screening and treatment access. HCV screening could be offered regularly in trans-specific health services, in the community, in jails and prisons, and integrated syringe exchange programs where treatment access or referral are also available.
Identifiants
pubmed: 33784365
doi: 10.1371/journal.pone.0249219
pii: PONE-D-20-33176
pmc: PMC8009419
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249219Subventions
Organisme : NIMHD NIH HHS
ID : T32 MD015070
Pays : United States
Organisme : NCHHSTP CDC HHS
ID : U62 PS005077
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Health Soc Care Community. 2013 Jul;21(4):402-10
pubmed: 23465052
Curr HIV/AIDS Rep. 2018 Apr;15(2):96-112
pubmed: 29460225
Psychiatr Rehabil J. 2015 Mar;38(1):45-54
pubmed: 25799305
BMC Infect Dis. 2014 Feb 10;14:74
pubmed: 24512462
J Viral Hepat. 2019 Jul;26(7):923-925
pubmed: 30809884
N Engl J Med. 1992 Dec 31;327(27):1899-905
pubmed: 1280771
Hepatology. 2009 Apr;49(4):1335-74
pubmed: 19330875
BMC Public Health. 2017 Feb 7;17(1):171
pubmed: 28173785
AIDS Care. 2020 May;32(sup2):74-82
pubmed: 32172589
PLoS One. 2018 Apr 11;13(4):e0195575
pubmed: 29641546
Clin Infect Dis. 2006 Apr 1;42(7):953-4
pubmed: 16511758
J Viral Hepat. 1995;2(3):113-9
pubmed: 7493305
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
J Infect Public Health. 2019 Jan - Feb;12(1):32-36
pubmed: 30170837
J Forensic Nurs. 2013 Jul-Sep;9(3):161-70
pubmed: 24158154
BMC Public Health. 2014 Jun 25;14:645
pubmed: 24965699
Am J Public Health. 2012 Sep;102(9):1751-7
pubmed: 22873480
Clin Infect Dis. 2008 Jun 15;46(12):1852-8
pubmed: 18462109
Public Health Rep. 2007;122 Suppl 1:39-47
pubmed: 17354526
J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):584-9
pubmed: 23334505
Am J Public Health. 2017 Sep;107(9):e12
pubmed: 28787216
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404
pubmed: 32271725
PLoS One. 2019 Jun 3;14(6):e0217471
pubmed: 31158245
Curr Drug Targets. 2017;18(7):851-862
pubmed: 26302808
J Int AIDS Soc. 2019 Apr;22(4):e25270
pubmed: 31037858
J Community Health. 2014 Oct;39(5):922-34
pubmed: 25135842
Addiction. 2009 Jan;104(1):69-76
pubmed: 19133890
Transfusion. 2005 Jun;45(6):994-1002
pubmed: 15934999
Int J Transgend. 2015;16(4):209-221
pubmed: 27110227
Am J Public Health. 2013 Aug;103(8):1485-92
pubmed: 23763398